Neimeth International Pharmaceuticals is a Nigerian drugmaker that has just pulled off a sharp turnaround: from a loss in 2024 to a solid profit in 2025, with shareholders backing a fresh capital raise to fund its next chapter. Full nameNeimeth International Pharmaceuticals Plc Tickers / exchangeNEIMETH.XNSA / Nigerian Exchange (NGX) HeadquartersLagos, Nigeria (AGM venue: NECA House, Alausa, Lagos) SectorPharmaceuticals EmployeesNot published in available sources Market valueNot published in available sources Yearly sales (revenue)₦7,368,524,000 (US$5.55 million) — year ended 31 Dec 2025 Net profit₦982,112,000 (US$739,700) — year ended 31 Dec 2025 …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Not ready to buy? Try Company Intelligence free for 14 days →
Editorial responsibility: Matthias Camenzind, Editor-in-Chief · Editorial standards · Report an error
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →